Lorlatinib in previously-treated ALK-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study
Abstract
Lorlatinib is a potent, brain-penetrant, 3rd-generation anaplastic lymphoma kinase (ALK)/ROS proto-oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) active against most known resistance mutations. This is an ongoing phase 1/2, multinational study (NCT01970865) investigating the efficacy, safety, and pharmacokinetics of lorlatinib in ALK-rearranged/ROS1-rearranged advanced non-small cell lung cancer (NSCLC) with or without intracranial (IC) metastases. Because patterns of ALK TKI use in Japan differ from other regions, we present a subgroup analysis among Japanese patients. Patients were enrolled into 6 expansion (EXP) cohorts based on ALK/ROS1 mutation status and treatment history. Primary endpoint was objective response rate (ORR) and IC-ORR by independent central review. Secondary endpoints included pharmacokinetic evaluations. At data cutoff, 39 ALK-rearranged /ROS1-rearranged Japanese patients were enrolled across the 6 expansion cohorts; all received lorlatinib 100 mg once daily. Thirty-one ALK-rearranged patients previously treated with ≥1 ALK TKI (EXP2 through EXP5) were evaluable for ORR and 15 were evaluable for IC-ORR. ORR and IC-ORR for Japanese in EXP2-5 were 54.8% (95% Confidence Interval [CI]: 36.0-72.7) and 46.7%...Continue Reading
References
Citations
Clinical Trials Mentioned
Related Concepts
Related Feeds
Attention Disorders
Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.